SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the company is a deep-value opportunity or a struggling incumbent in the face of competitive pressure from agentic AI. While community members are polarized over recent price declines, the core discussion focuses on the firm's cash-rich, debt-free balance sheet and its potential for a turnaround through its ongoing strategic pivot toward enterprise AI orchestration.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is capturing significant investor attention following the expansion of its multi-year compute agreement with Meta, now valued at over $35 billion, and a new strategic partnership to power Anthropic's Claude models. While the community is actively debating the stock's potential for a major breakout and the impact of its aggressive infrastructure debt financing, sentiment remains divided between those betting on the company's critical role in the AI compute race and skeptics wary of its long-term leverage and potential for shareholder dilution.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing significant downward pressure and all-time low sentiment despite an investor day focused on long-term growth through a new midsize vehicle platform, robotaxi ambitions, and potential partnerships. Community members are sharply divided, with bulls pointing to Saudi financial backing and future product cycles as a deep-value opportunity, while bears remain fixated on persistent cash burn, recurring vehicle recalls, and the stock's ongoing decline.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense debate as investors weigh strong government contract momentum against skepticism from figures like Michael Burry, whose recent commentary has fueled volatility. Sentiment is further polarized by a high-profile presidential endorsement, which has sparked aggressive discussion about potential market manipulation versus legitimate valuation corrections in the AI software sector.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is facing high volatility as investors weigh strong quarterly revenue growth and AI product momentum against broader sector-wide concerns about AI-driven disruption. While the community is debating whether the current sell-off reflects a structural shift or a temporary repricing of software multiples, many are watching key technical support levels to see if the stock can stabilize after its recent breakdown.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing a sharp sell-off as investors grapple with sector-wide pressure and growing concerns that AI-driven disruption from companies like Anthropic could commoditize traditional enterprise software. While the stock has hit fresh multi-year lows, the community remains deeply divided, with some calling for capitulation and others identifying the pullback as a generational buying opportunity tied to the company's long-term enterprise infrastructure role.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors react to a recent analyst upgrade and the company's decision to walk away from a potential Warner Bros. Discovery acquisition, with the community closely tracking its momentum toward the key $100 resistance level. Bullish sentiment is fueled by expectations of strong organic growth, while traders remain highly focused on upcoming earnings and potential technical breakouts.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is currently seeing intense investor activity as the community reacts to its recent foundry integration news and growing momentum in the photonics sector. Traders are closely tracking the stock's ability to maintain its newfound price levels while debating whether this is a sustainable breakout driven by institutional accumulation or a speculative move vulnerable to broader market volatility.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is seeing intense market interest and a sharp price surge driven by unconfirmed headlines regarding a potential $12 billion acquisition bid by Sun Pharma. While the community is actively debating the credibility of the reports and the impact of the company's significant debt load, the stock remains a focal point for M&A speculators and those tracking a potential breakout.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is currently trending as a community-driven memecoin that leverages long-standing internet lore to position itself as a satirical counterpoint to Bitcoin. Participants are actively discussing its potential for significant market movement, focusing on the cultural irony of its 'store of butts' branding and its origins within historical crypto forums.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anthem (NASDAQ:ANTX) Stock Price Up 1.2% - Still a Buy?

Anthem (NASDAQ:ANTX) Shares Up 1.2% - Still a Buy...

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry...

AN2 Therapeutics Stock Cools Off After 90% Rally

AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.read more...

Power Hour Surge: Biotech Cash Floods, Energy Breakouts, and AI Bets Drive the Stocks to Watch into the Close

As Wall Street heads into the final stretch of the trading day, capital flows into biotech financing, clean energy, and emerging technology platforms are shaping the stocks traders are watching most closely into the close and after-hours session. $EONR, $SAFX, $KBLB, $HIMS, $MDCX, $ANTX, $NVO, $MDCX, $RLMD, $SLDB, $ANTX, $EDIT, $DDD

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced a $40 million private placement financing.read more...

<ul class="summary-bullets"><li>AN2 Therapeutics is expected to sell more than eight million shares of common stock at $2.85 per share.</li><li>The private placement includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital.</li><li>The stock has gained more than&nbsp;500% over four sessions since the company announced positive results for its blood cancer treatment.</li></ul>Shares of AN2 Therapeutics (ANTX) surged more than 110% on Monday, after the clinical-stage biopharmaceutical company announced that it signed a securities purchase agreement for a private placement expected to raise about $40 million in gross proceeds.<a href="https://stocktwits.com/symbol/ANTX">ANTX shares</a> recorded their biggest-ever intraday gains.As part of the deal, AN2 Therapeutics will sell 8.25 million shares of common stock at $2.85 per share, which was also the stock’s closing price on Friday. The company also offered investors the option to purchase pre-funded warrants to acquire up to 5.79 million additional shares at nearly the same price, with an exercise price of&nbsp;$0.00001 per share.The private placement is expected to close on March 10, 2026, and includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital, along with other new and existing shareholders. AN2 Therapeutics did not disclose how it plans to use the proceeds from the offering.<h2 class="st-heading-2">500% Rally After Epetraborole Update</h2>The stock has been on an extraordinary rally, adding nearly 500% over four sessions since the company announced plans to further develop its drug epetraborole into a Phase 2 proof-of-concept study for patients with Polycythemia Vera (PV) who rely on phlebotomy treatments.PV is a blood cancer that causes the bone marrow to produce too many red blood cells, increasing the risk of serious complications such as blood clots.Last week, AN2 Therapeutics said that its oral epetraborole produced consistent and sustained reductions in hematocrit across several studies involving healthy volunteers and other patient groups. The company expects to begin the Phase 2 study in the third quarter of 2026 and plans to provide initial trial updates by the following quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ANTX_jpg_31ad151992.webp" alt="ANTX.jpg">One user highlighted the various resistance levels, speculating that the stock could climb as high as $108.<stembedurl>https://stocktwits.com/M105/message/647014265</stembedurl>However, another expressed confusion over the “bullish excitement.”<stembedurl>https://stocktwits.com/Tradeforlosses/message/647018987</stembedurl>Year-to-date, the stock has gained more than 400%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iran-warns-of-crude-hitting-200-a-barrel-if-energy-infrastructure-is-targeted-report/cZdVpreRIIr">Iran Warns Of Crude Hitting $200 A Barrel If Energy Infrastructure Is Targeted: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Equity

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has...

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to...

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder...

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley in 2017 and is headquartered in Menlo Park, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.23	--	--	N/A
Q4 '25	-$0.24	-$0.29	-20.83%	MISSED
Q3 '25	-$0.22	-$0.31	-40.91%	MISSED
Q2 '25	-$0.34	-$0.21	37.31%	BEAT
Q1 '25	-$0.26	-$0.35	-32.08%	MISSED

ANTX
AN2 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ANTX News

ANTXAN2 Therapeutics Inc